Video

How do we get the next 10 years right? w/ Joanna Shields, CogX

For the opening keynote of CogX 2020, our CEO Joanna Shields shared inspiration for the next decade, and answered the question “how do we get the next 10 years right”?

We had entered 2020 with such high hopes and dreams for the innovations that awaited us in the coming decade. Yet we were barely out of the gates when our world of infinite possibilities was brought to its knees by a deadly virus. The challenges that followed have been unprecedented in our lifetimes. 

As the disease raged through our communities and lockdowns were enforced, we all watched the daily news recount the number of souls who had lost their lives to COVID-19.  The profound economic shock continues to reverberate, and expose deep inequities in our society and in how we care for our citizens.

Our journey into this strange new normal also made us painfully aware of our own vulnerabilities and the fragility of human life. Above all, we have been reminded that our most valuable currency is not measured in wealth or possessions, but rather through our health.  

So, why can’t we build a world where no disease goes untreated? Why, with all of the advances in technology, are so many people still suffering from disease? The economic and development models urgently need to change. Patients deserve better. We must leverage breakthrough technologies for the benefit of all.

Above all, getting the next 10 years right demands leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all.

Watch the full speech here:


More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022